Table 3.

Pooled clinical activity

	APG-1387 monotherapy trial	APG-1387 combination trial
n	23	22
Best overall response, n (%)
Complete response	0 (0)	1 (4·5)
Partial response	0 (0)	2 (9·1)
Stable disease	5 (21·7)	9 (40·9)
Progressive disease	18 (78·3)	10 (45·5)
Not evaluable	5 (21·7)	0 (0)
Objective response rate	0 (0)	3 (13·6)
95% confidence interval	0-0	2·9-34·9
Disease control rate	5 (21·7)	12 (54·5)
95% confidence interval	7·46-43·70	32·2-75·6
Duration of response (months)	NA	NR [8·4-NR]
95% confidence interval	NA	NR

Data are presented as number (percentage of patients) or median (interquartile range) unless otherwise specified.

NA, not applicable; NR, not reached.